I take my blood pressure medication twice a day and honestly it's fine. I don't see why BID dosing is such a big deal? People take Tylenol multiple times a day without complaints. Is the pharma industry overthinking this?

Fair push-back, and you're right that millions of people successfully manage BID medications. The issue is more nuanced:

• Acute vs. chronic medications: Taking Tylenol BID for a headache is fine. Taking a medication BID for the rest of your life is a different compliance challenge.
• GI side effect timing: With a GLP-1 RA, each dose can trigger nausea. BID dosing means potentially feeling nauseous twice per day instead of once. That's a qualitatively worse patient experience.
• Competitive context: If a once-daily pill with better efficacy and tolerability is available (orforglipron), why would a patient or prescriber choose a twice-daily pill with worse numbers? In a monopoly, BID is fine. In a competitive market, it's a significant disadvantage.
• Meal coordination: Some GLP-1 RAs interact with food. BID dosing creates two meal-coordination events per day instead of one.

It's not that BID is unworkable. It's that in a market where the competition offers QD dosing with better efficacy, BID is a hard sell.

I want to give Pfizer some credit for transparency though. When their Phase 2 data was disappointing, they acknowledged it publicly and pivoted strategy. Many companies would have pushed forward with an inferior formulation hoping to salvage the investment. Pfizer made the hard call to go back to formulation development, which will cost them years but could yield a better product.

The modified-release formulation is being studied in new Phase 1/2 trials now. Early PK data should tell us whether they've successfully extended the half-life enough for once-daily dosing. If the MR formulation works AND they can demonstrate efficacy closer to orforglipron, danuglipron could still have a commercial future — just a later one.

What about the ALT elevation signal that was mentioned? That seems more concerning than the dosing frequency issue. Liver toxicity would be a much bigger problem than having to take a pill twice a day.

Good catch. The ALT elevations observed in danuglipron Phase 2 were mostly mild and reversible, but they were dose-dependent and occurred at a higher rate than placebo. This raised a flag because:

1. Other GLP-1 RAs (semaglutide, tirzepatide) actually improve liver enzymes via weight loss
2. If a drug targeting obesity worsens liver enzymes even transiently, it creates concern about hepatotoxicity risk in a population with high rates of underlying fatty liver disease
3. The FDA scrutinizes hepatic safety signals closely — this could complicate the regulatory pathway

Pfizer has stated that the ALT elevations resolved after dose stabilization and were not associated with clinical hepatitis. But it's something that will need careful monitoring in future trials, and the MR formulation's smoother PK profile might actually help by avoiding the high peak drug levels that could drive hepatic stress.